Drospirenone and cardiovascular risk in lean and obese polycystic ovary syndrome patients: a pilot study

Fulvia Mancini, Arianna Cianciosi, Nicola Persico, Fabio Facchinetti, Paolo Busacchi, Cesare Battaglia

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: We sought to verify if an oral contraceptive (OC) containing drospirenone affects the cardiovascular risk of patients with polycystic ovary syndrome (PCOS). Study Design: A total of 28 women with PCOS (16 lean [group A] and 12 overweight [group B]) were assessed at baseline and after 6 months therapy with an OC. Leptin, homocysteine, endothelin-1, and flow-mediated dilatation of brachial artery were measured. Results: The brachial artery diameter and the pulsatility index, after the reactive hyperemia, did not change in group A; it improved significantly in group B after 6 months of treatment. At baseline and after therapy the plasma levels of homocysteine and endothelin-1 did not differ among the groups. Leptin was significantly lower at baseline in group A compared to group B. Conclusion: The OC containing drospirenone does not seem to affect the surrogate markers of cardiovascular risk in lean patients with PCOS.

Original languageEnglish
JournalAmerican Journal of Obstetrics and Gynecology
Volume202
Issue number2
DOIs
Publication statusPublished - Feb 2010

Fingerprint

Polycystic Ovary Syndrome
Oral Contraceptives
Brachial Artery
Homocysteine
Endothelin-1
Leptin
Hyperemia
Dilatation
Therapeutics
Biomarkers
drospirenone

Keywords

  • Drospirenone
  • endothelin-1
  • flow-mediated dilatation
  • leptin
  • polycystic ovary syndrome

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Drospirenone and cardiovascular risk in lean and obese polycystic ovary syndrome patients : a pilot study. / Mancini, Fulvia; Cianciosi, Arianna; Persico, Nicola; Facchinetti, Fabio; Busacchi, Paolo; Battaglia, Cesare.

In: American Journal of Obstetrics and Gynecology, Vol. 202, No. 2, 02.2010.

Research output: Contribution to journalArticle

Mancini, Fulvia ; Cianciosi, Arianna ; Persico, Nicola ; Facchinetti, Fabio ; Busacchi, Paolo ; Battaglia, Cesare. / Drospirenone and cardiovascular risk in lean and obese polycystic ovary syndrome patients : a pilot study. In: American Journal of Obstetrics and Gynecology. 2010 ; Vol. 202, No. 2.
@article{6456ffa1fb234acb853db1ae89b42c8a,
title = "Drospirenone and cardiovascular risk in lean and obese polycystic ovary syndrome patients: a pilot study",
abstract = "Objective: We sought to verify if an oral contraceptive (OC) containing drospirenone affects the cardiovascular risk of patients with polycystic ovary syndrome (PCOS). Study Design: A total of 28 women with PCOS (16 lean [group A] and 12 overweight [group B]) were assessed at baseline and after 6 months therapy with an OC. Leptin, homocysteine, endothelin-1, and flow-mediated dilatation of brachial artery were measured. Results: The brachial artery diameter and the pulsatility index, after the reactive hyperemia, did not change in group A; it improved significantly in group B after 6 months of treatment. At baseline and after therapy the plasma levels of homocysteine and endothelin-1 did not differ among the groups. Leptin was significantly lower at baseline in group A compared to group B. Conclusion: The OC containing drospirenone does not seem to affect the surrogate markers of cardiovascular risk in lean patients with PCOS.",
keywords = "Drospirenone, endothelin-1, flow-mediated dilatation, leptin, polycystic ovary syndrome",
author = "Fulvia Mancini and Arianna Cianciosi and Nicola Persico and Fabio Facchinetti and Paolo Busacchi and Cesare Battaglia",
year = "2010",
month = "2",
doi = "10.1016/j.ajog.2009.09.038",
language = "English",
volume = "202",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Drospirenone and cardiovascular risk in lean and obese polycystic ovary syndrome patients

T2 - a pilot study

AU - Mancini, Fulvia

AU - Cianciosi, Arianna

AU - Persico, Nicola

AU - Facchinetti, Fabio

AU - Busacchi, Paolo

AU - Battaglia, Cesare

PY - 2010/2

Y1 - 2010/2

N2 - Objective: We sought to verify if an oral contraceptive (OC) containing drospirenone affects the cardiovascular risk of patients with polycystic ovary syndrome (PCOS). Study Design: A total of 28 women with PCOS (16 lean [group A] and 12 overweight [group B]) were assessed at baseline and after 6 months therapy with an OC. Leptin, homocysteine, endothelin-1, and flow-mediated dilatation of brachial artery were measured. Results: The brachial artery diameter and the pulsatility index, after the reactive hyperemia, did not change in group A; it improved significantly in group B after 6 months of treatment. At baseline and after therapy the plasma levels of homocysteine and endothelin-1 did not differ among the groups. Leptin was significantly lower at baseline in group A compared to group B. Conclusion: The OC containing drospirenone does not seem to affect the surrogate markers of cardiovascular risk in lean patients with PCOS.

AB - Objective: We sought to verify if an oral contraceptive (OC) containing drospirenone affects the cardiovascular risk of patients with polycystic ovary syndrome (PCOS). Study Design: A total of 28 women with PCOS (16 lean [group A] and 12 overweight [group B]) were assessed at baseline and after 6 months therapy with an OC. Leptin, homocysteine, endothelin-1, and flow-mediated dilatation of brachial artery were measured. Results: The brachial artery diameter and the pulsatility index, after the reactive hyperemia, did not change in group A; it improved significantly in group B after 6 months of treatment. At baseline and after therapy the plasma levels of homocysteine and endothelin-1 did not differ among the groups. Leptin was significantly lower at baseline in group A compared to group B. Conclusion: The OC containing drospirenone does not seem to affect the surrogate markers of cardiovascular risk in lean patients with PCOS.

KW - Drospirenone

KW - endothelin-1

KW - flow-mediated dilatation

KW - leptin

KW - polycystic ovary syndrome

UR - http://www.scopus.com/inward/record.url?scp=74749101212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74749101212&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2009.09.038

DO - 10.1016/j.ajog.2009.09.038

M3 - Article

C2 - 19913778

AN - SCOPUS:74749101212

VL - 202

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 2

ER -